FCF Yield

Quest Diagnostics' current free cash flow (FCF) yield of 5.7% measures the cash generated per share relative to its stock price, indicating how much cash return an investor gets for each dollar invested.

This sits well above the healthcare sector median of 3.6%, placing the company in the 82nd percentile among its peers — meaning DGX offers a higher cash yield than most competitors. Year-over-year change is not available, but quarter-over-quarter the FCF yield fell 9.5% from the prior value of 6.3%, showing a recent decline. While the above-median level suggests a relatively attractive cash return compared to the sector, the downward quarterly trend signals that this advantage may be eroding. The combination of a high percentile rank and a recent drop points to a mixed risk profile: the yield is still favorable but requires monitoring to see if the decline persists. This directly supports the overall NEUTRAL verdict, as the strong relative yield is balanced by the weakening quarterly momentum.

Frequently Asked Questions

Closest Sector Peers